Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
CMTM4
is the most conserved member of chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing (CMTM) family on chromosome 16q22.1, a locus that harbors a number of tumor-suppressor genes. In previous studies,
CMTM4
was reported to be downregulated and exhibited tumor-suppressor activities by regulating cell growth and cell cycle in clear cell renal cell carcinoma. However, its roles in tumorigenesis of
hepatocellular carcinoma
(
HCC
) remain poorly studied. This study first investigated the expression of
CMTM4
in
HCC
, and then examined the association between the expression of
CMTM4
with the clinicopathological features and prognosis of
HCC
patients. It was found that
CMTM4
was downregulated in
HCC
tissues, compared with matched adjacent nontumor tissues, as detected by immunohistochemistry. In addition, Kaplan-Meier survival analysis showed that the negative expression of
CMTM4
was associated with decreased overall survival rates in patients with
HCC
. The results of this study suggest
CMTM4
plays a role as a tumor suppressor in
HCC
and
CMTM4
negative expression is a risk factor for poor prognosis of
HCC
.
...
PMID:Clinical significance of CMTM4 expression in hepatocellular carcinoma. 2918 Aug 77
CMTM4
(
CKLF-like MARVEL transmembrane domain containing 4
), a potential tumor suppressor gene, is involved in several types of malignancies. It has been reported to be downregulated and exhibit anti-tumorigenic activities by regulating cell growth and cell cycle in clear cell renal cell carcinoma. It has also been identified as a tumor suppressor in
hepatocellular carcinoma
(
HCC
), and its negative expression is a risk factor for poor prognosis of
HCC
patients. In the present study, an integrated bioinformatics analysis based on The Cancer Genome Atlas (TCGA) database showed that
CMTM4
was frequently reduced in colorectal cancer (CRC) and high expression of
CMTM4
was associated with increased overall survival rates. Based on these findings, we adopted gain-of-function and lost-of-function strategies using SW480 and HT29 CRC cell lines which have relatively low and high endogenous
CMTM4
levels, respectively. We observed impeded cell proliferation and migration upon overexpression of
CMTM4
in SW480 cells, and the opposite effects were observed upon knockdown of
CMTM4
in HT-29 cells. Cell signaling pathways essential for CRC progression were then examined, and the phosphorylation levels of AKT, ERK1/2, and STAT3 were found to be decreased by
CMTM4
overexpression in SW480 cells and elevated by
CMTM4
silencing in HT29 cells. Their inhibitors were used to validate that the three signaling pathways contributed to the inhibitory effects of
CMTM4
on CRC cells. Taken together, our results suggest that
CMTM4
plays a tumor suppressive role in CRC.
...
PMID:CMTM4 inhibits cell proliferation and migration via AKT, ERK1/2, and STAT3 pathway in colorectal cancer. 3143 38
